{"id":1755,"date":"2015-04-08T22:11:41","date_gmt":"2015-04-08T22:11:41","guid":{"rendered":"http:\/\/ingelyt.com\/en\/?p=1755"},"modified":"2017-11-14T19:31:35","modified_gmt":"2017-11-14T19:31:35","slug":"pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5","status":"publish","type":"post","link":"https:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/","title":{"rendered":"PHARMACEUTICAL FACILITIES TO FACE THE NEW GMP CHAPTERS 3 AND 5"},"content":{"rendered":"

1. INTRODUCTION<\/strong><\/h2>\n

Last modifications on European GMP, which are taking effect on Mach 15th<\/sup>, (Chapter 3 and especially Chapter 5) are going to impact on existing facilities and equipment, and they are going to force a rethinking of all steps and measures to be taken in order to avoid cross contamination; not just for these products so-called \u201chigh potency\u201d but in general for all pharmaceutical products. Every pharmaceutical product must have a risk analysis based on a toxicological assessment. Measures to be taken in order to avoid cross contamination will be determined in accordance with a risk analysis, based on the Quality Risk Management principles and they should be commensurate with the risks<\/p>\n

2. THE OLD LACK OF DEFINITION: \u201cGET READY FOR THE WORST\u201d<\/strong><\/h2>\n

On previous versions of Chapter 3 and 5 dedicated facilities and containment measures were recommended for \u201ccertain hormones, certain antibiotics, certain cytotoxics<\/em>\u2026.\u201dbut there was no further information\u00a0 about which hormones, antibiotics or cytotixics could be considered among these \u201ccertains<\/em>\u201d That lack of definition give rise to two kind of facilities: High containment facilities and standard facilities. When in doubt about the categorization of a product this was branded as \u201cHigh Potency \u201cand it was processed in dedicated facilities or high containment facilities with all those measures for high containment: Once through air systems, Bag In\/Bag out filters, closed process, PPE for autonomous breathing, decontamination showers\u2026 The advice was: \u201cIn doubt get ready for the worst\u201d but it meant expensive facilities and high energy costs.<\/p>\n

3. THE NEW APROACH: \u201cEVERY PICTURE TELLS A STORY\u201d<\/strong>.<\/h2>\n

With the new GMP approach a risk analysis based on the Quality Risk Management principles\u00a0 is mandatory for any medicinal product\u00a0 and\u00a0 the analysis must include a toxicological evaluation for every case, not just for \u201ccertain hormones, certain antibiotics, certain cytotoxics\u2026.\u201d<\/em>\u00a0 This risk analysis should be used to assess and control the cross-contamination risks presented by the products manufactured and measures to be taken should be commensurate<\/strong> with the risks. Thus there are no longer two options: high containment or standard manufacture; from now on there will be as may options as risk degrees and specific containment or protection measures should be defined for each case .<\/p>\n

4. STRESS TEST NOT JUST FOR BANKS\u00a0<\/strong><\/h2>\n

Risk analysis and toxicological evaluations are going to be a real \u201cstress test<\/strong>\u201d that will bring up lacks and deficiencies \u00a0in some current facilities which should be adapted to the new regulations; but on the other hand, all of these facilities which manage to fulfill the new regulations will have a wide open door to manufacturing these products which were considered\u00a0 just in the border of \u201cHigh Potecncy\u201d and, in accordance to the old saying of getting\u00a0 ready for the worst, they required high energy cost and expensive facilities and equipment. Now, with a correct application of the regulations it will be possible to manufacture \u201ccertain\u201d medicinal products in facilities with reasonable operating costs.<\/p>\n

5. THE CLOCK IS TICKING <\/strong><\/h2>\n

New changes in GMP will become effective in March 1st 2015. There will be a leeway of some months for risk analysis and toxicological evaluation in order to categorize the products in current manufacturing or to be manufactured. June 2015 for new products to be manufactured in a multiproduct facility, and December 2015 for products under current manufacturing.\u00a0 The critical point will be to use risk analysis and toxicological evaluation checking if facilities and equipment are adequate to avoid cross contamination.<\/p>\n

6. CONCLUSION <\/strong><\/h2>\n

There are medicinal products, and there will be more and more, which will require dedicated\u00a0 and high containment\u00a0 facilities, more and more complex and sophisticated; but at the same time there are a wide range of products located just under the concept of \u201cHigh Potency\u201d which, in the light of the new approach on Chapter 3 and 5, will require measures for control contamination and containment commensurate<\/strong> with the risk<\/strong>, both at technical and operating levels. In this way small or moderate refurbishment of the facilities could open up new opportunities\u00a0 of manufacturing with competitive operating costs compared with these on the classic dedicated or high containment facilities.<\/p>\n

Miguel Ruiz<\/p>\n

mruiz@ingelyt.com<\/p>\n","protected":false},"excerpt":{"rendered":"

Last modifications on European GMP, which are taking effect on Mach 15th, (Chapter 3 and especially Chapter 5) are going to impact on existing facilities and equipment, and they are going to force a rethinking of all steps and measures to be taken in order to avoid cross contamination; not just for these products so-called \u201chigh potency\u201d but in general for all pharmaceutical products. Every pharmaceutical product must have a risk analysis based on a toxicological assessment. Measures to be taken in order to avoid cross contamination will be determined in accordance with a risk analysis, based on the Quality Risk Management principles and they should be commensurate with the risks<\/p>\n","protected":false},"author":5,"featured_media":2186,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50,64],"tags":[79,78],"class_list":["post-1755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clean-rooms","category-pharmaceutical-support","tag-cross-contamination-prevention","tag-gmp-3-and-5-chapters"],"yoast_head":"\nPHARMACEUTICAL FACILITIES TO FACE THE NEW GMP CHAPTERS 3 AND 5 - Ingelyt - Engineering and installations<\/title>\n<meta name=\"description\" content=\"Pharmaceutical facilities to face the new GMP chapters 3 and 5 in order to prevent the risk of cross contamination\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PHARMACEUTICAL FACILITIES TO FACE THE NEW GMP CHAPTERS 3 AND 5 - Ingelyt - Engineering and installations\" \/>\n<meta property=\"og:description\" content=\"Pharmaceutical facilities to face the new GMP chapters 3 and 5 in order to prevent the risk of cross contamination\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/\" \/>\n<meta property=\"og:site_name\" content=\"Ingelyt - Engineering and installations\" \/>\n<meta property=\"article:published_time\" content=\"2015-04-08T22:11:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-11-14T19:31:35+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/ingelyt.com\/en\/wp-content\/uploads\/sites\/2\/2017\/11\/hapi-potent-active-ingredient-ingelyt-ingeneering-clean-rooms-consulting-gmp.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"748\" \/>\n\t<meta property=\"og:image:height\" content=\"748\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Miguel Ruiz\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Miguel Ruiz\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/\",\"url\":\"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/\",\"name\":\"PHARMACEUTICAL FACILITIES TO FACE THE NEW GMP CHAPTERS 3 AND 5 - Ingelyt - Engineering and installations\",\"isPartOf\":{\"@id\":\"https:\/\/ingelyt.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/#primaryimage\"},\"image\":{\"@id\":\"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ingelyt.com\/en\/wp-content\/uploads\/sites\/2\/2017\/11\/hapi-potent-active-ingredient-ingelyt-ingeneering-clean-rooms-consulting-gmp.jpg\",\"datePublished\":\"2015-04-08T22:11:41+00:00\",\"dateModified\":\"2017-11-14T19:31:35+00:00\",\"author\":{\"@id\":\"https:\/\/ingelyt.com\/en\/#\/schema\/person\/a4b47000fa1b8eb1c5966a18e1d77933\"},\"description\":\"Pharmaceutical facilities to face the new GMP chapters 3 and 5 in order to prevent the risk of cross contamination\",\"breadcrumb\":{\"@id\":\"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/#primaryimage\",\"url\":\"https:\/\/ingelyt.com\/en\/wp-content\/uploads\/sites\/2\/2017\/11\/hapi-potent-active-ingredient-ingelyt-ingeneering-clean-rooms-consulting-gmp.jpg\",\"contentUrl\":\"https:\/\/ingelyt.com\/en\/wp-content\/uploads\/sites\/2\/2017\/11\/hapi-potent-active-ingredient-ingelyt-ingeneering-clean-rooms-consulting-gmp.jpg\",\"width\":748,\"height\":748,\"caption\":\"HAPI potent active ingredient - Ingelyt Clean Room Engineering - GMP Consulting\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ingelyt.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clean rooms\",\"item\":\"https:\/\/ingelyt.com\/en\/blog\/category\/clean-rooms\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"PHARMACEUTICAL FACILITIES TO FACE THE NEW GMP CHAPTERS 3 AND 5\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ingelyt.com\/en\/#website\",\"url\":\"https:\/\/ingelyt.com\/en\/\",\"name\":\"Ingelyt - Engineering and installations\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ingelyt.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ingelyt.com\/en\/#\/schema\/person\/a4b47000fa1b8eb1c5966a18e1d77933\",\"name\":\"Miguel Ruiz\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ingelyt.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ca05e1e75ff9c9d77c95200f6e72cdac?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ca05e1e75ff9c9d77c95200f6e72cdac?s=96&d=mm&r=g\",\"caption\":\"Miguel Ruiz\"},\"url\":\"https:\/\/ingelyt.com\/en\/blog\/author\/miguel-ruiz\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PHARMACEUTICAL FACILITIES TO FACE THE NEW GMP CHAPTERS 3 AND 5 - Ingelyt - Engineering and installations","description":"Pharmaceutical facilities to face the new GMP chapters 3 and 5 in order to prevent the risk of cross contamination","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/","og_locale":"en_US","og_type":"article","og_title":"PHARMACEUTICAL FACILITIES TO FACE THE NEW GMP CHAPTERS 3 AND 5 - Ingelyt - Engineering and installations","og_description":"Pharmaceutical facilities to face the new GMP chapters 3 and 5 in order to prevent the risk of cross contamination","og_url":"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/","og_site_name":"Ingelyt - Engineering and installations","article_published_time":"2015-04-08T22:11:41+00:00","article_modified_time":"2017-11-14T19:31:35+00:00","og_image":[{"width":748,"height":748,"url":"http:\/\/ingelyt.com\/en\/wp-content\/uploads\/sites\/2\/2017\/11\/hapi-potent-active-ingredient-ingelyt-ingeneering-clean-rooms-consulting-gmp.jpg","type":"image\/jpeg"}],"author":"Miguel Ruiz","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Miguel Ruiz","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/","url":"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/","name":"PHARMACEUTICAL FACILITIES TO FACE THE NEW GMP CHAPTERS 3 AND 5 - Ingelyt - Engineering and installations","isPartOf":{"@id":"https:\/\/ingelyt.com\/en\/#website"},"primaryImageOfPage":{"@id":"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/#primaryimage"},"image":{"@id":"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/#primaryimage"},"thumbnailUrl":"https:\/\/ingelyt.com\/en\/wp-content\/uploads\/sites\/2\/2017\/11\/hapi-potent-active-ingredient-ingelyt-ingeneering-clean-rooms-consulting-gmp.jpg","datePublished":"2015-04-08T22:11:41+00:00","dateModified":"2017-11-14T19:31:35+00:00","author":{"@id":"https:\/\/ingelyt.com\/en\/#\/schema\/person\/a4b47000fa1b8eb1c5966a18e1d77933"},"description":"Pharmaceutical facilities to face the new GMP chapters 3 and 5 in order to prevent the risk of cross contamination","breadcrumb":{"@id":"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/#primaryimage","url":"https:\/\/ingelyt.com\/en\/wp-content\/uploads\/sites\/2\/2017\/11\/hapi-potent-active-ingredient-ingelyt-ingeneering-clean-rooms-consulting-gmp.jpg","contentUrl":"https:\/\/ingelyt.com\/en\/wp-content\/uploads\/sites\/2\/2017\/11\/hapi-potent-active-ingredient-ingelyt-ingeneering-clean-rooms-consulting-gmp.jpg","width":748,"height":748,"caption":"HAPI potent active ingredient - Ingelyt Clean Room Engineering - GMP Consulting"},{"@type":"BreadcrumbList","@id":"http:\/\/ingelyt.com\/en\/blog\/pharmaceutical-facilities-to-face-the-new-gmp-chapters-3-and-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ingelyt.com\/en\/"},{"@type":"ListItem","position":2,"name":"Clean rooms","item":"https:\/\/ingelyt.com\/en\/blog\/category\/clean-rooms\/"},{"@type":"ListItem","position":3,"name":"PHARMACEUTICAL FACILITIES TO FACE THE NEW GMP CHAPTERS 3 AND 5"}]},{"@type":"WebSite","@id":"https:\/\/ingelyt.com\/en\/#website","url":"https:\/\/ingelyt.com\/en\/","name":"Ingelyt - Engineering and installations","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ingelyt.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ingelyt.com\/en\/#\/schema\/person\/a4b47000fa1b8eb1c5966a18e1d77933","name":"Miguel Ruiz","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ingelyt.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ca05e1e75ff9c9d77c95200f6e72cdac?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ca05e1e75ff9c9d77c95200f6e72cdac?s=96&d=mm&r=g","caption":"Miguel Ruiz"},"url":"https:\/\/ingelyt.com\/en\/blog\/author\/miguel-ruiz\/"}]}},"_links":{"self":[{"href":"https:\/\/ingelyt.com\/en\/wp-json\/wp\/v2\/posts\/1755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ingelyt.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ingelyt.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ingelyt.com\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/ingelyt.com\/en\/wp-json\/wp\/v2\/comments?post=1755"}],"version-history":[{"count":3,"href":"https:\/\/ingelyt.com\/en\/wp-json\/wp\/v2\/posts\/1755\/revisions"}],"predecessor-version":[{"id":1758,"href":"https:\/\/ingelyt.com\/en\/wp-json\/wp\/v2\/posts\/1755\/revisions\/1758"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ingelyt.com\/en\/wp-json\/wp\/v2\/media\/2186"}],"wp:attachment":[{"href":"https:\/\/ingelyt.com\/en\/wp-json\/wp\/v2\/media?parent=1755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ingelyt.com\/en\/wp-json\/wp\/v2\/categories?post=1755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ingelyt.com\/en\/wp-json\/wp\/v2\/tags?post=1755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}